CureDose Biotechnology

CureDose Biotechnology is a South Korean biopharmaceutical company specialized in the development of next-generation targeted radiopharmaceuticals for oncology. The company utilizes its proprietary CureDose Targeting (CDT) platform to design high-affinity protein and peptide-based ligands that deliver therapeutic radionuclides specifically to cancer cells. Their current pipeline focuses on established and novel targets for solid tumors, including prostate cancer, neuroendocrine tumors, and pancreatic cancer. By optimizing the pharmacokinetic profiles of their radioligands, CureDose aims to maximize therapeutic efficacy while minimizing off-target radiation exposure. The firm is positioned as an innovator in the growing field of Targeted Alpha Therapy (TAT) and radioligand therapeutics within the Asian biotech landscape.